Literature DB >> 21862150

Outcomes of patients with chronic kidney disease and implantable cardiac defibrillator: primary versus secondary prevention.

Fadi G Hage1, Wael Aljaroudi, Himanshu Aggarwal, Vikas Bhatia, John Miller, Harish Doppalapudi, Oussama Wazni, Ami E Iskandrian.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is associated with worse survival in patients with implantable cardiac defibrillators (ICDs). This study examined the association of outcomes with CKD in patients receiving an ICD for primary versus secondary prevention.
METHODS: The study included 696 patients who underwent ICD placement for clinical reasons (59% primary, 41% secondary prevention) at the University of Alabama at Birmingham between January 2002 and September 2007. CKD was defined as an estimated glomerular filtration rate<60 ml/min/1.73 m(2) but not on dialysis. Outcomes of interest included overall mortality and first appropriate ICD therapy (shocks or anti-tachycardia pacing).
RESULTS: After a follow-up of 50 ± 24 months, 213 patients died (31%) and 111 (16%) received appropriate ICD therapy. Patients with CKD had higher mortality than patients with no CKD in the primary (43% vs. 15%, p<0.001) and secondary prevention (37% vs. 23%, p = 0.003) groups. Patients with CKD were at higher risk of receiving an appropriate ICD therapy than patients without CKD in the primary (p<0.001) but not secondary prevention (p = 0.9) cohort. After adjusting for age, gender and multiple risk factors, CKD was independently associated with all-cause mortality and ICD therapy in the primary prevention group (HR 2.08 [1.34-3.23] and 3.53 [1.75-7.10], p = 0.001 and <0.0001, respectively) but not in the secondary prevention group (HR 1.27 [0.81-2.00], and 0.63 [0.35-1.13], p=0.3 and 0.2, respectively).
CONCLUSIONS: CKD is independently associated with increased mortality and appropriate ICD therapy in patients undergoing ICD implantation for primary but not secondary prevention.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21862150     DOI: 10.1016/j.ijcard.2011.07.087

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

1.  Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators.

Authors:  Nisha Bansal; Adam Szpiro; Frederick Masoudi; Robert T Greenlee; David H Smith; David J Magid; Jerry H Gurwitz; Kristi Reynolds; Grace H Tabada; Sue Hee Sung; Ashveena Dighe; Andrea Cassidy-Bushrow; Romel Garcia-Montilla; Stephen Hammill; John Hayes; Alan Kadish; Param Sharma; Paul Varosy; Humberto Vidaillet; Alan S Go
Journal:  Heart       Date:  2016-10-14       Impact factor: 5.994

2.  Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study).

Authors:  Wael A AlJaroudi; Marwan M Refaat; Robert H Habib; Laila Al-Shaar; Madhurmeet Singh; Rebecca Gutmann; Heather L Bloom; Samuel C Dudley; Patrick T Ellinor; Samir F Saba; Alaa A Shalaby; Raul Weiss; Dennis M McNamara; Indrani Halder; Barry London
Journal:  Am J Cardiol       Date:  2015-01-15       Impact factor: 2.778

3.  Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.

Authors:  Patrick H Pun; Anne S Hellkamp; Gillian D Sanders; John P Middleton; Stephen C Hammill; Hussein R Al-Khalidi; Lesley H Curtis; Gregg C Fonarow; Sana M Al-Khatib
Journal:  Nephrol Dial Transplant       Date:  2014-11-17       Impact factor: 5.992

4.  Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.

Authors:  Giuseppe Boriani; Irina Savelieva; Gheorghe-Andrei Dan; Jean Claude Deharo; Charles Ferro; Carsten W Israel; Deirdre A Lane; Gaetano La Manna; Joseph Morton; Angel Moya Mitjans; Marc A Vos; Mintu P Turakhia; Gregory Y H Lip
Journal:  Europace       Date:  2015-06-24       Impact factor: 5.214

Review 5.  Predictors of mortality and ICD shock therapy in primary prophylactic ICD patients-A systematic review and meta-analysis.

Authors:  Leonard Bergau; Tobias Tichelbäcker; Barbora Kessel; Lars Lüthje; Thomas H Fischer; Tim Friede; Markus Zabel
Journal:  PLoS One       Date:  2017-10-17       Impact factor: 3.240

6.  Mortality in patients on renal replacement therapy and permanent cardiac pacemakers.

Authors:  Gabriel Vanerio; Cristina García; Carlota González; Alejandro Ferreiro
Journal:  Int J Nephrol       Date:  2014-05-26

Review 7.  Gender Differences in Appropriate Shocks and Mortality among Patients with Primary Prophylactic Implantable Cardioverter-Defibrillators: Systematic Review and Meta-Analysis.

Authors:  David Conen; Barbora Arendacká; Christian Röver; Leonard Bergau; Pascal Munoz; Sofieke Wijers; Christian Sticherling; Markus Zabel; Tim Friede
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

8.  Impact of Chronic Kidney Disease on Short-Term Cardiac Implantable Electronic Device Related Infection: A Nationwide Population-Based Cohort Study.

Authors:  Yu-Sheng Lin; Tien-Hsing Chen; Ming-Shyan Lin; Dong Yi Chen; Chun-Tai Mao; Jen-Te Hsu; Huang-Chung Chen; Mien-Cheng Chen
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.